Invention Grant
- Patent Title: Anti-PCNA monoclonal antibodies and use thereof
-
Application No.: US17074919Application Date: 2020-10-20
-
Publication No.: US11667700B2Publication Date: 2023-06-06
- Inventor: Ari-Angel Porgador
- Applicant: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
- Applicant Address: IL Beer-Sheva
- Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
- Current Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
- Current Assignee Address: IL Beer-Sheva
- Agency: The Roy Gross Law Firm, LLC
- Agent Roy Gross
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K39/395 ; G01N33/574 ; C07K16/18 ; A61P35/02 ; A61K39/00
Abstract:
The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.
Public/Granted literature
- US20210032320A1 ANTI-PCNA MONOCLONAL ANTIBODIES AND USE THEREOF Public/Granted day:2021-02-04
Information query
